Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy

被引:27
作者
Garg, Amit K. [1 ]
Oh, Julia L. [1 ]
Oswald, Mary Jane [1 ]
Huang, Eugene [1 ]
Strom, Eric A. [1 ]
Perkins, George H. [1 ]
Woodward, Wendy A. [1 ]
Yu, T. Kuan [1 ]
Tereffe, Welela [1 ]
Meric-Bernstam, Funda [2 ]
Hahn, Karin [3 ]
Buchholz, Thomas A. [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1202, Houston, TX 77030 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 05期
关键词
radiation therapy; mastectomy; young age; neoadjuvant chemotherapy;
D O I
10.1016/j.ijrobp.2007.05.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Postmastectomy radiotherapy (PMRT) improves locoregional control (LRC) in patients with high-risk features after mastectomy. Young age continues to evolve as a potentially important risk factor. The objective of this study was to assess the benefits of PMRT in patients < 35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer. Patients and Methods: We retrospectively analyzed 107 consecutive breast cancer patients < 35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT. The treatment groups were compared in terms of LRC and overall survival. Results: Despite more advanced disease stages, the patients who received PMRT (n = 80) had greater rates of LRC (5-year rate, 88% vs. 63%,p = 0.001) and better overall survival (5-year rate, 67% vs. 48%,p = 0.03) than patients who did not receive PMRT (n = 27). Conclusion: Among breast cancer patients < 35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT. The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions after mastectomy. (c) 2007 Elsevier Inc.
引用
收藏
页码:1478 / 1483
页数:6
相关论文
共 50 条
  • [31] The Role of Postmastectomy Radiation Therapy After Neoadjuvant Chemotherapy in Clinical Stage II-III Breast Cancer Patients With pN0: A Multicenter, Retrospective Study (KR0G 12-05)
    Shim, Su Jung
    Park, Won
    Huh, Seung Jae
    Choi, Doo Ho
    Shin, Kyung Hwan
    Lee, Nam Kwon
    Suh, Chang-Ok
    Keum, Ki Chang
    Kim, Yong Bae
    Do Ahn, Seung
    Kim, Su Ssan
    Ha, Sung W.
    Chie, Eui Kyu
    Kim, Kyubo
    Shin, Hyun Soo
    Kim, Jin Hee
    Lee, Hyung-Sik
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (01): : 65 - 72
  • [32] Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
    Yang, Yaewon
    Im, Seock-Ah
    Keam, Bhumsuk
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Suh, Koung Jin
    Ryu, Han Suk
    Moon, Hyeong-Gon
    Han, Sae-Won
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Park, In Ae
    Noh, Dong-Young
    [J]. BMC CANCER, 2016, 16
  • [33] Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
    Yaewon Yang
    Seock-Ah Im
    Bhumsuk Keam
    Kyung‑Hun Lee
    Tae‑Yong Kim
    Koung Jin Suh
    Han Suk Ryu
    Hyeong-Gon Moon
    Sae‑Won Han
    Do‑Youn Oh
    Wonshik Han
    Tae‑You Kim
    In Ae Park
    Dong-Young Noh
    [J]. BMC Cancer, 16
  • [34] Does internal mammary node irradiation affect treatment outcome in clinical stage II-III breast cancer patients receiving neoadjuv ant chemotherapy?
    Kim, Kyung Hwan
    Noh, Jae Myoung
    Kim, Yong Bae
    Chang, Jee Suk
    Keum, Ki Chang
    Huh, Seung Jae
    Choi, Doo Ho
    Park, Won
    Suh, Chang-Ok
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 589 - 599
  • [35] Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
    Duc Thanh Le
    Lap Thanh Bui
    Chu Van Nguyen
    Kien Hung Do
    Giang Le Tran
    Tu Anh Do
    [J]. Oncology and Therapy, 2023, 11 : 327 - 341
  • [36] Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
    Le, Duc Thanh
    Bui, Lap Thanh
    Nguyen, Chu Van
    Do, Kien Hung
    Tran, Giang Le
    Do, Tu Anh
    [J]. ONCOLOGY AND THERAPY, 2023, 11 (03) : 327 - 341
  • [37] Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients
    So-Youn Jung
    Kyung Hwan Shin
    Myungsoo Kim
    Seung Hyun Chung
    Seeyoun Lee
    Han-Sung Kang
    Eun Sook Lee
    Youngmee Kwon
    Keun Seok Lee
    In Hae Park
    Jungsil Ro
    [J]. Breast Cancer Research and Treatment, 2014, 148 : 91 - 98
  • [38] FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients
    Caroline Rousseau
    Anne Devillers
    Mario Campone
    Loïc Campion
    Ludovic Ferrer
    Christine Sagan
    Myriam Ricaud
    Boumédiène Bridji
    Françoise Kraeber-Bodéré
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 1029 - 1036
  • [39] FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients
    Rousseau, Caroline
    Devillers, Anne
    Campone, Mario
    Campion, Loic
    Ferrer, Ludovic
    Sagan, Christine
    Ricaud, Myriam
    Bridji, Boumediene
    Kraeber-Bodere, Francoise
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (06) : 1029 - 1036
  • [40] Impact of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates Surgical Results From CALGB 40603 (Alliance)
    Golshan, Mehra
    Cirrincione, Constance T.
    Sikov, William M.
    Berry, Donald A.
    Jasinski, Sara
    Weisberg, Tracey F.
    Somlo, George
    Hudis, Clifford
    Winer, Eric
    Ollila, David W.
    [J]. ANNALS OF SURGERY, 2015, 262 (03) : 434 - 439